koto_feja/iStock via Getty Images
When Intellia (NASDAQ:NTLA) presented their interim data on their lead drug candidate treating transthyretin amyloidosis (ATTR), NTLA-2001, it shocked the medical and investor community by proving gene editing has the potential to vastly outperform current standard-of-care therapies. Since then, the
Analyst’s Disclosure: I/we have a beneficial long position in the shares of NTLA, CRSP either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.
